Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin with or without bintrafusp alfa as first-line treatment of biliary tract cancer
2019-001992-35Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bintrafusp alfa in biliary cancer (3 arms), sponsored by Merck KGaA. Primary endpoint: Safety and tolerability in open-label run-in. Started Oct 2019; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
biliary cancer
Beyond the preview
Go deeper on 2019-001992-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001992-35.